艾司西酞普兰联合奥氮平治疗躯体形式障碍对照研究

A comparative study of escitalopram combined with olanzapine in the treatment of somatoform disorders

目的探讨艾司西酞普兰联合奥氮平治疗躯体形式障碍的效果和安全性,为提高躯体形式障碍的疗效提供参考。方法将60例躯体形式障碍患者按照随机数字表法分为2组,每组30例,均予以口服艾司西酞普兰治疗,研究组在此基础上联合奥氮平治疗,观察8周。于治疗前后采用症状自评量表(SCL-90)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评定临床疗效,采用副反应量表(TESS)评定不良反应。结果治疗8周末研究组总有效率高于对照组(P<0.05)。治疗后第2、4、8周末2组SCL-90躯体化因子分、HAMA及HAMD总分均较各自治疗前降低(P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论艾司西酞普兰联合奥氮平对躯体形式障碍的疗效优于单用艾司西酞普兰,二者安全性相当。

Objective To investigate the efficacy and safety of escitalopram combined with olanzapine in the treatment of somatic form disorder,and to provide reference for improving the efficacy of somatic form disorder.Methods 60 patients with somatoform disorder were randomly divided into two groups and 30 patients in each group were treated with oral escitalopram.The research group was treated with olanzapine on this basis and observed for 8 weeks.Clinical efficacy was assessed by symptom self-rating scale(scl-90),Hamilton anxiety scale(HAMD)and Hamilton depression scale(HAMA)before and after treatment,and adverse reactions were assessed by TESS.Results The results of the study were as the following:the total effective rate of the study group at the end of the 8 th week was higher than that of the control group(P<0.05),and after treatment at the 2 nd,4 th and 8 th week,the total scores of somatic factors,HAMA and HAMD in SCL-90 were lower than those before treatment(P<0.05).Also there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of Escitalopram combined with Olanzapine in the treatment of somatoform disorders is better than that of Escitalopram alone,certainly with equivalent safety.